{"id":5401,"date":"2025-12-24T15:49:52","date_gmt":"2025-12-24T12:49:52","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=5401"},"modified":"2025-12-24T15:57:40","modified_gmt":"2025-12-24T12:57:40","slug":"italfarmaco-jcr-pharmaceuticals-duvyzat-givinostat-japan","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/italfarmaco-jcr-pharmaceuticals-duvyzat-givinostat-japan\/","title":{"rendered":"Italfarmaco et JCR Pharmaceuticals annoncent un accord de commercialisation du Duvyzat (givinostat) au Japon et une collaboration strat\u00e9gique dans le domaine des maladies rares"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Italfarmaco et JCR Pharmaceuticals ont annonc\u00e9 un accord de licence exclusif pour le d\u00e9veloppement et la commercialisation du Duvyzat (Givinostat) au Japon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aux termes de l&#039;accord, JCR obtient les droits exclusifs de commercialisation du givinostat pour le traitement de la dystrophie musculaire de Duchenne (DMD) au Japon et sera responsable de la mise en \u0153uvre locale des activit\u00e9s de d\u00e9veloppement clinique, ainsi que des soumissions r\u00e9glementaires. <a href=\"https:\/\/dmdwarrior.com\/fr\/duvyzat-givinostat-nonsteroidal-drug\/\" target=\"_blank\" data-type=\"post\" data-id=\"3957\" rel=\"noreferrer noopener\">Qu&#039;est-ce que le Givinostat ?<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le givinostat (commercialis\u00e9 sous le nom de Duvyzat\u00ae aux \u00c9tats-Unis, au Royaume-Uni et dans l&#039;Union europ\u00e9enne) est un inhibiteur de l&#039;histone d\u00e9sac\u00e9tylase administr\u00e9 par voie orale, d\u00e9velopp\u00e9 par Italfarmaco pour le traitement de la dystrophie musculaire de Duchenne (DMD), quelle que soit la mutation du g\u00e8ne de la dystrophine sous-jacente. Il a obtenu une autorisation de mise sur le march\u00e9 dans plusieurs grands pays, dont les \u00c9tats-Unis, l&#039;Union europ\u00e9enne et le Royaume-Uni\u00a0; il n&#039;est actuellement pas autoris\u00e9 au Japon.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&#039;accord \u00e9tablit \u00e9galement une collaboration strat\u00e9gique plus large entre les deux entreprises afin d&#039;explorer des opportunit\u00e9s communes pour le traitement des maladies rares.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c Ce partenariat repr\u00e9sente une \u00e9tape cl\u00e9 de notre strat\u00e9gie mondiale visant \u00e0 \u00e9largir l&#039;acc\u00e8s au givinostat et \u00e0 renforcer notre impact dans le domaine des maladies rares \u201d, a d\u00e9clar\u00e9 Antonio Nardi, vice-pr\u00e9sident et directeur du d\u00e9veloppement commercial et du portefeuille d&#039;Italfarmaco. \u201c L&#039;engagement de JCR en faveur de l&#039;innovation, sa solide expertise locale et son approche scientifique centr\u00e9e sur le patient en font un partenaire id\u00e9al pour le d\u00e9veloppement de nos portefeuilles de produits pour les maladies rares, non seulement au Japon, mais aussi \u00e0 l&#039;international. \u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>En savoir plus<\/strong>:&nbsp;<a href=\"https:\/\/dmdwarrior.com\/fr\/dmd-therapies\/\" target=\"_blank\" rel=\"noreferrer noopener\">Essais cliniques sur la dystrophie musculaire de Duchenne (Liste de toutes les recherches)<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Italfarmaco and JCR Pharmaceuticals announced an exclusive licensing agreement for the development and commercialisation of Duvyzat (Givinostat) in Japan. Under the terms of the agreement, JCR receives exclusive rights to commercialise givinostat for the treatment of Duchenne muscular dystrophy (DMD) in Japan and will be responsible for the local execution of clinical development activities, as [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5402,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[46,47,311,142,385],"class_list":["post-5401","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-duvyzat","tag-givinostat","tag-italfarmaco","tag-japan","tag-jcr-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5401","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=5401"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/5401\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/5402"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=5401"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=5401"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=5401"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}